6NQM

Crystal structure of Human LSD1

Summary for 6NQM

• Entry DOI: 10.2210/pdb6nqm/pdb
• Descriptor: Lysine-specific histone demethylase 1A, FLAVIN-ADENINE DINUCLEOTIDE (2 entities in total)
• Functional Keywords: lysine-specific histone demethylase, cofactor, oxidoreductase
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 1
• Total formula weight: 74091.39

Authors

Tan, A.H.Y.,Tu, W.,McCuaig, R.,Donovan, T.,Tsimbalyuk, S.,Forwood, J.K.,Rao, S. (deposition date: 2019-01-21, release date: 2019-02-13, Last modification date: 2023-10-11)

Primary citation

Tan, A.H.Y.,Tu, W.,McCuaig, R.,Hardy, K.,Donovan, T.,Tsimbalyuk, S.,Forwood, J.K.,Rao, S.
Lysine-Specific Histone Demethylase 1A Regulates Macrophage Polarization and Checkpoint Molecules in the Tumor Microenvironment of Triple-Negative Breast Cancer.
Front Immunol, 10:1351-1351, 2019

PubMed Abstract: Macrophages play an important role in regulating the tumor microenvironment (TME). Here we show that classical (M1) macrophage polarization reduced expression of LSD1, nuclear REST corepressor 1 (CoREST), and the zinc finger protein SNAIL. The LSD1 inhibitor phenelzine targeted both the flavin adenine dinucleotide (FAD) and CoREST binding domains of LSD1, unlike the LSD1 inhibitor GSK2879552, which only targeted the FAD domain. Phenelzine treatment reduced nuclear demethylase activity and increased transcription and expression of M1-like signatures both and in a murine triple-negative breast cancer model. Overall, the LSD1 inhibitors phenelzine and GSK2879552 are useful tools for dissecting the contribution of LSD1 demethylase activity and the nuclear LSD1-CoREST complex to switching macrophage polarization programs. These findings suggest that inhibitors must have dual FAD and CoREST targeting abilities to successfully initiate or prime macrophages toward an anti-tumor M1-like phenotype in triple-negative breast cancer.

PubMed: 31249575
DOI: 10.3389/fimmu.2019.01351

Experimental method

X-RAY DIFFRACTION (2.9 Å)